Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Gastrointestinal Neoplasms 1Gastroesophageal Reflux 1Barrett Esophagus 1

Interventions

Oxaliplatin 5S 1 (combination) 4Irinotecan 4pembrolizumab 3IFL protocol 3Fluorouracil 3Bevacizumab 3amminedichloro(2-methylpyridine)platinum(II) 2N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 2MLN 8237 2Leucovorin 2Gemcitabine 2Folfox protocol 2Fecal Microbiota Transplantation 2Drug Therapy 2Doxorubicin 2Cyclophosphamide 2Cisplatin 2Cetuximab 2Capecitabine 2CGX1321 2ulixertinib 1tivozanib 1titanium silicide 1tislelizumab 1sodium thiosulfate 1sacituzumab govitecan 1remune 1plecanatide 1phosphatidyltransferase, Clostridium butyricum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gastrointestinal Neoplasms × plecanatide × Clear all
NCT05107219 2026-04-07

GCC Agonist Signal in the Small Intestine

University of Wisconsin, Madison

Phase 1 Completed
43 enrolled
Gastrointestinal

Barrett Esophagus, Gastroesophageal Reflux, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡